Published online Nov 26, 2019. doi: 10.12998/wjcc.v7.i22.3859
Peer-review started: April 23, 2019
First decision: September 9, 2019
Revised: October 9, 2019
Accepted: October 15, 2019
Article in press: October 15, 2019
Published online: November 26, 2019
Processing time: 219 Days and 19.2 Hours
Macrophage activation syndrome (MAS) is defined as a specific secondary hemophagocytic lymphohistiocytosis that refers particularly to those triggered by autoimmune diseases. MAS is a rare and highly lethal complication of systemic lupus erythematosus (SLE), which can be associated with, or mimic, disease flare. However, the data regarding the clinical course, management and outcome of SLE with MAS is limited, especially in adults. Lack of clinical recognition of the disease often leads to poor prognosis.
We report a 36-year-old Chinese woman without relevant past medical history who was admitted to hospital with a 6-d history of jaundice and a high fever of 39.4°C lasting one day. Abdominal magnetic resonance imaging excluded obstructive jaundice, no infection was identified and empiric superior antibiotic treatment (meropenem) showed no clinical improvement. However, newly emerged pancytopenia and respiratory failure endangered the patient’s life. Autoimmune work-up finally led to the diagnosis of SLE, which initially presented as MAS and manifested respiratory failure, although neither bone marrow biopsy nor lymph node biopsy showed hemophagocytosis. To our knowledge, such a scenario has never been reported in detail before. The patient had a favorable reaction to combination treatment with corticosteroid and cyclosporine A and has been in clinical remission during the 1-year follow up period.
Respiratory failure and MAS can be an onset of SLE. Early diagnosis and appropriate treatment are extremely important for a better prognosis.
Core tip: We report a 36-year-old Chinese woman diagnosed with systemic lupus erythematosus who initially presented with macrophage activation syndrome (MAS) and manifested respiratory failure. The administration of corticosteroid and cyclosporine A improved her respiratory depression along with all other symptoms. The clinical characteristics of MAS show great heterogeneity, and sufficient knowledge of these syndromes and early diagnosis are essential to improve prognosis. Corticosteroids are the mainstay of initial treatment for MAS.